Valuation: Positron Corporation

Market Cap 56.49M 50.69M 46.86M 42.44M 79.29M 5.38B 80.25M 560M 223M 2.82B 212M 208M 8.94B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 55.36M 49.67M 45.92M 41.59M 77.7M 5.27B 78.64M 549M 219M 2.76B 208M 203M 8.76B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+2.15%
1 week+15.57%
Current month+6.26%
1 month+1.60%
3 months+18.68%
6 months+2.70%
Current year+13.77%
1 week 1.67
Extreme 1.6725
1.91
1 month 1.43
Extreme 1.43
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+15.57%+16.35%+52.00% 56.49M
+1.61%+1.46%+26.28%+63.22% 256B
+0.89%+0.09%+7.92%+24.58% 163B
-0.38%+3.75%-18.56%+71.51% 155B
-5.84%-4.67%-57.98%-14.32% 65.3B
+1.06%+3.82%+11.67%+48.73% 52.35B
+1.72%+2.11%-12.83%-7.13% 51.93B
+1.39%-0.85%+9.09%+67.70% 50.75B
+2.25%+2.10%+24.43%+76.59% 50.04B
+1.78%+4.24%+37.85%+94.84% 46.03B
Average +0.66%+1.56%+4.42%+47.77% 89.05B
Weighted average by Cap. +0.59%+1.68%+5.32%+49.58%

Financials

2024 2025
Net sales 588K 527K 487K 441K 825K 55.95M 835K 5.83M 2.32M 29.28M 2.2M 2.16M 92.95M 461K 414K 383K 347K 648K 43.95M 655K 4.58M 1.82M 23M 1.73M 1.7M 73.01M
Net income -2.38M -2.13M -1.97M -1.79M -3.34M -227M -3.38M -23.6M -9.4M -119M -8.93M -8.74M -376M -10.6M -9.51M -8.8M -7.97M -14.88M -1.01B -15.06M -105M -41.89M -528M -39.79M -38.95M -1.68B
Net Debt 1.42M 1.28M 1.18M 1.07M 2M 136M 2.02M 14.13M 5.63M 70.99M 5.35M 5.23M 225M -1.14M -1.02M -942K -854K -1.59M -108M -1.61M -11.27M -4.49M -56.62M -4.26M -4.17M -180M
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
26-10-27 $1.720 +1.18% 13,651
26-10-26 $1.700 +1.49% 215
26-10-23 $1.675 +2.76% 110
26-10-22 $1.630 -0.85% 5,469
26-10-21 $1.644 -4.57% 819
  1. Stock Market
  2. Stocks
  3. POSC Stock